These individual shares are significantly greater than Diovan/Tareg’s current patient share and so are higher than the patient share attained by any current hypertension drug. In the crowded hypertension market, 25 to thirty % individual shares are unlikely reached without the evidence of long-term clinical benefit. However, the magnitude of these estimates indicate cardiologists’ concern about individual compliance to therapy and their desire for a novel drug that requires less-regular dosing than Diovan/Tareg, so long as this agent has similar cardioprotective results as Diovan/Tareg, stated Decision Resources Therapeutic Region Director Nikhil Mehta, M.Eng.Savvy, ahead-of-the-curve companies across Europe are capitalising on e-detailing as a low-cost opportunity to increase physician engagement and improve the overall sales call quality. Five Emerging Styles about European Consumer and Physician Use of New Media 1. Connecting to Doctors, on Their Conditions 2. Leverage E-detailing as a SALES TEAM Health supplement 3. Online Physician Portals Evolve into Clinical Assets, Beyond Information 4. Empowered European Consumers Speak with Their Physician about Info Found Online 5.